Association between fibromyalgia syndrome and peptic ulcer disease development

Kevin A Wang; Jia-Chi Wang; Cheng-Li Lin; Chun-Hung Tseng

doi:10.1371/journal.pone.0175370

Association between fibromyalgia syndrome and peptic ulcer disease development

PLoS One. 2017 Apr 6;12(4):e0175370. doi: 10.1371/journal.pone.0175370. eCollection 2017.

Authors

Kevin A Wang^{1

2}, Jia-Chi Wang³, Cheng-Li Lin^{4

5}, Chun-Hung Tseng^{6

7}

Affiliations

¹ Division of General Surgery, Department of Surgery, Shin-Kong Memorial Hospital, Taipei, Taiwan.
² School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
³ Department of Physical Medicine and Rehabilitation, National Yang-Ming University and Taipei Veterans General Hospital, Taipei, Taiwan.
⁴ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.
⁵ College of Medicine, China Medical University, Taichung, Taiwan.
⁶ Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
⁷ Department of Neurology, China Medical University Hospital, Taichung, Taiwan.

Abstract

Purpose: The correlation of fibromyalgia syndrome (FMS) with peptic ulcer disease (PUD) is unclear. We therefore conducted a cohort study to investigate whether FMS is correlated with an increased risk of PUD.

Methods: In this study, we established an FMS cohort comprising 26068 patients aged more than 20 years who were diagnosed with FMS from 2000 to 2011. Furthermore, we established a control cohort by randomly choosing 104269 people without FMS who were matched to the FMS patients by gender, age, and index year. All patients were free of PUD at the baseline. Cox proportional hazard regressions were performed to compute the hazard ratio of PUD after adjustment for demographic characteristics and comorbidities.

Results: The prevalence of comorbidities was significantly higher in the FMS patients than in the controls. The incidence of PUD was 29.8 and 19.4 per 1000 person-years in the FMS and control cohorts, respectively. In addition, the FMS cohort exhibited a 1.40-fold higher risk of PUD (95% confidence interval = 1.35-1.45) compared with the control cohort. After control for confounding factors, the medications (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and antidepressants) taken by the FMS patients did not increase the risk of PUD.

Conclusion: FMS patients exhibit a higher risk of PUD than that of patients without FMS.

MeSH terms

Aged
Cohort Studies
Female
Fibromyalgia / complications*
Humans
Male
Middle Aged
Peptic Ulcer / complications*
Proportional Hazards Models
Risk Factors

Grants and funding

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B-039 -005); the Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.